Display options
Cite
Lee CW, Liu ME, Lee TM, et al. Patient satisfaction with dabigatrean and warfarin for stroke prevention in atrial fibrillation: Taiwan PASSION study. J Chin Med Assoc. 2021;84(4):375-382doi: 10.1097/JCMA.0000000000000496.
Lee, C. W., Liu, M. E., Lee, T. M., Chang, R. Y., Huang, C. Y., Hu, Y. F., & Yeh, H. I. (2021). Patient satisfaction with dabigatrean and warfarin for stroke prevention in atrial fibrillation: Taiwan PASSION study. Journal of the Chinese Medical Association : JCMA, 84(4), 375-382. https://doi.org/10.1097/JCMA.0000000000000496
Lee, Chun-Wei, et al. "Patient satisfaction with dabigatrean and warfarin for stroke prevention in atrial fibrillation: Taiwan PASSION study." Journal of the Chinese Medical Association : JCMA vol. 84,4 (2021): 375-382. doi: https://doi.org/10.1097/JCMA.0000000000000496
Lee CW, Liu ME, Lee TM, Chang RY, Huang CY, Hu YF, Yeh HI. Patient satisfaction with dabigatrean and warfarin for stroke prevention in atrial fibrillation: Taiwan PASSION study. J Chin Med Assoc. 2021 Apr 01;84(4):375-382. doi: 10.1097/JCMA.0000000000000496. PMID: 33784265.
Copy Download .nbib Format: NLM
Share it on

J Chin Med Assoc. 2021 Apr 01;84(4):375-382. doi: 10.1097/JCMA.0000000000000496.

Patient satisfaction with dabigatrean and warfarin for stroke prevention in atrial fibrillation: Taiwan PASSION study.

Journal of the Chinese Medical Association : JCMA

Chun-Wei Lee, Ming-En Liu, Tsung-Ming Lee, Rei-Yeuh Chang, Chun-Yao Huang, Yu-Feng Hu, Hung-I Yeh

Affiliations

  1. Cardiovascular Division, Department of Internal Medicine, MacKay Memorial Hospital, MacKay Medical College, New Taipei City, Taiwan, ROC.
  2. MacKay Junior College of Medicine, Nursing and Management, Taipei, Taiwan, ROC.
  3. Cardiovascular Division, Landseed International Hospital, Taoyuan, ROC.
  4. Hsinchu MacKay Memorial Hospital, Hsinchu, Taiwan, ROC.
  5. Cardiovascular Institute, An Nan Hospital, China Medical University, Tainan, Taiwan, ROC.
  6. Department of Medicine, China Medical University, Taichung, Taiwan, ROC.
  7. Division of Cardiology, Chia-Yi Christian Hospital, Chiayi, Taiwan, ROC.
  8. Division of Cardiology, Taipei Medical University Hospital, Taipei, Taiwan, ROC.
  9. Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.

PMID: 33784265 DOI: 10.1097/JCMA.0000000000000496

Abstract

BACKGROUND: Patient satisfaction with oral anticoagulant (OAC) therapy is an important metric of care quality and has been associated with higher medication persistence. Among OACs, dabigatran has been shown to be non-inferior to vitamin K antagonists (VKAs) with increased ease of use for stroke prevention in patients with atrial fibrillation (AF). In this study, we sought to evaluate the expectations, convenience, and satisfaction of Taiwanese AF patients on dabigatran and VKA therapies as well as associated clinical outcomes.

METHODS: Patients with AF (paroxysmal, persistent, or permanent) receiving OAC medication from outpatient facilities were enrolled in 24 hospitals across Taiwan. Cohort A consisted of 139 patients switched from VKA to dabigatran, while cohort B was comprised of 1113 patients on newly initiated OAC therapy (VKA, 54). The Perception of Anticoagulant Treatment Questionnaire was distributed, and responses on a five-point Likert scale were aggregated and analyzed across demographic groups.

RESULTS: In cohort A, convenience and satisfaction scores continued to increase at follow-up and significantly higher, compared to baseline, but both treatments scored similarly in cohort B. In cohort B, the two highest expectation scores were that the OAC would be "easy to take" and could be "taken independently." On the other hand, the patients were relatively less concerned about the side effects and cost of therapy before taking the OAC. For dabigatran-receiving patients, there were 1.1 stroke-related events per 100 patient-years and 3.0 bleeding-related events per 100 patient-years.

CONCLUSION: In Taiwanese patients with AF and initially treated with VKA, switched to dabigatran resulted in higher convenience and treatment satisfaction. For those patients on newly initiated OAC treatment, VKA and dabigatran convenience and satisfaction scores were similar.

Copyright © 2021, the Chinese Medical Association.

Conflict of interest statement

Conflicts of interest: The authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article.

References

  1. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014; 129:837–47 - PubMed
  2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22:983–8 - PubMed
  3. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014; 383:955–62 - PubMed
  4. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. RE-LY Steering Committee and InvestigatorsDabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361:1139–51 - PubMed
  5. Kjerpeseth LJ, Ellekjær H, Selmer R, Ariansen I, Furu K, Skovlund E. Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015. Eur J Clin Pharmacol. 2017; 73:1417–25 - PubMed
  6. Ko YJ, Kim S, Park K, Kim M, Yang BR, Kim MS, et al. Impact of the health insurance coverage policy on oral anticoagulant prescription among patients with atrial fibrillation in Korea from 2014 to 2016. J Korean Med Sci. 2018; 33:e163 - PubMed
  7. Seong JY, Shin BJ, Jang CH, Yang HC. Safety and patients’ satisfaction of fungal ball removal in the maxillary sinus under local anesthesia. Int J Gerontol. 2019; 13:251–4 - PubMed
  8. Oh C, Kang H. Effects of Tai Chi exercise on the body composition, self-efficacy and life satisfaction of older adults in Korean local community. Int J Gerontol. 2019; 13:134–8 - PubMed
  9. Prins MH, Guillemin I, Gilet H, Gabriel S, Essers B, Raskob G, et al. Scoring and psychometric validation of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q). Health Qual Life Outcomes. 2009; 7:30 - PubMed
  10. Admassie E, Chalmers L, Bereznicki LR. Changes in oral anticoagulant prescribing for stroke prevention in patients with atrial fibrillation. Am J Cardiol. 2017; 120:1133–8 - PubMed
  11. Obamiro KO, Chalmers L, Lee K, Bereznicki BJ, Bereznicki LRE. Anticoagulation knowledge in patients with atrial fibrillation: an Australian survey. Int J Clin Pract. 2018; 72:e13072 - PubMed
  12. Cajfinger F, Debourdeau P, Lamblin A, Benatar V, Falvo N, Benhamou Y, et al. TROPIQUE investigatorsLow-molecular-weight heparins for cancer-associated thrombosis: adherence to clinical practice guidelines and patient perception in TROPIQUE, a 409-patient prospective observational study. Thromb Res. 2016; 144:85–92 - PubMed
  13. Smet L, Heggermont WA, Goossens E, Eeckloo K, Vander Stichele R, De Potter T, et al. Adherence, knowledge, and perception about oral anticoagulants in patients with atrial fibrillation at high risk for thromboembolic events after radiofrequency ablation. J Adv Nurs. 2018; 74:2577–87 - PubMed
  14. Larochelle J, Brais C, Blais L, Perreault S, Farand P, Letemplier G, et al. Patients’ perception of newly initiated oral anticoagulant treatment for atrial fibrillation: an observational study. J Gen Intern Med. 2018; 33:1239–41 - PubMed
  15. Okumura Y, Yokoyama K, Matsumoto N, Tachibana E, Kuronuma K, Oiwa K, et al. SAKURA AF Registry InvestigatorsPatient satisfaction with direct oral anticoagulants and warfarin. Int Heart J. 2018; 59:1266–74 - PubMed
  16. Goette A, Kwong WJ, Ezekowitz MD, Banach M, Hjortshoj SP, Zamoryakhin D, et al. Edoxaban therapy increases treatment satisfaction and reduces utilization of healthcare resources: an analysis from the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of atrial fibrillation (ENSURE-AF) study. Europace. 2018; 20:1936–43 - PubMed
  17. Benzimra M, Bonnamour B, Duracinsky M, Lalanne C, Aubert JP, Chassany O, et al. Real-life experience of quality of life, treatment satisfaction, and adherence in patients receiving oral anticoagulants for atrial fibrillation. Patient Prefer Adherence. 2018; 12:79–87 - PubMed
  18. Keita I, Aubin-Auger I, Lalanne C, Aubert JP, Chassany O, Duracinsky M, et al. Assessment of quality of life, satisfaction with anticoagulation therapy, and adherence to treatment in patients receiving long-course vitamin K antagonists or direct oral anticoagulants for venous thromboembolism. Patient Prefer Adherence. 2017; 11:1625–34 - PubMed
  19. Gospos J, Bernaitis N. Treatment expectations, convenience, and satisfaction with anticoagulant treatment: perceptions of patients in South-East Queensland, Australia. J Clin Med. 2019; 8:863 - PubMed
  20. MacLean S, Mulla S, Akl EA, Jankowski M, Vandvik PO, Ebrahim S, et al. Patient values and preferences in decision making for antithrombotic therapy: a systematic review: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 1412 Supple1S–e23S - PubMed
  21. Mazurek M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, et al. GLORIA-AF InvestigatorsSafety and effectiveness of dabigatran at 2 years: final outcomes from Phase II of the GLORIA-AF registry program. Am Heart J. 2019; 218:123–7 - PubMed
  22. Lip GY, Clemens A, Noack H, Ferreira J, Connolly SJ, Yusuf S. Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. Thromb Haemost. 2014; 111:933–42 - PubMed

Publication Types